AMERICA’s Food and Drug
Administration (FDA) is updating
labelling requirements for
metformin-containing medicines
used to treat diabetes, after a
review of studies found metformin
can be used safely in patients
with mild impairment in kidney
function and in some patients with
moderate impairment.
As well as updating labels to
reflect this new information, the
FDA is recommending that the
measure of kidney function used to
determine whether a patient can
receive metformin be changed to
glomerular filtration rate estimating
equation (eGFR).
More details at www.fda.gov.The above article was sent to subscribers in Pharmacy Daily's issue from 11 Apr 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Apr 16
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.